Publication
Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results
| dc.contributor.author | Silva, RM | |
| dc.contributor.author | Ruiz-Moreno, JM | |
| dc.contributor.author | Rosa, P | |
| dc.contributor.author | Carneiro, A | |
| dc.contributor.author | Nascimento, J | |
| dc.contributor.author | Rito, LF | |
| dc.contributor.author | Cachulo, ML | |
| dc.contributor.author | Carvalheira, F | |
| dc.contributor.author | Murta, JN | |
| dc.date.accessioned | 2014-07-31T10:40:49Z | |
| dc.date.available | 2014-07-31T10:40:49Z | |
| dc.date.issued | 2010 | |
| dc.description.abstract | PURPOSE: The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia. METHODS: This was a prospective, multicenter, consecutive, nonrandomized, interventional case series. The study included 34 eyes of 32 patients with choroidal neovascularization secondary to pathologic myopia; 13 eyes had previous photodynamic therapy, and 21 eyes had no previous treatment. The patients were followed for > or = 12 months. Best-corrected visual acuity, optical coherence tomography, and the presence of metamorphopsia were assessed monthly. RESULTS: Mean visual acuity improved 8 letters from baseline to 12-month follow-up, and the difference was statistically significant (P < 0.001): 100% of the eyes lost <3 lines on the Early Treatment Diabetic Retinopathy Study chart, 24% of the eyes improved > or = 3 lines, 44% improved > or = 2 lines, 65% improved > or = 1 line, and 79% improved > or = 0 lines. Central retinal thickness decreased significantly from baseline to the 12-month follow-up (P < 0.01). A mean of 3.6 treatments were performed during the 12-month follow-up, and no systemic or ocular side effects were registered during that time. CONCLUSION: One-year results of intravitreal ranibizumab for myopic choroidal neovascularization are very promising. Additional prospective studies are necessary to better determine long-term efficacy and safety. | por |
| dc.identifier.citation | Retina. 2010;30(3):407-12. doi: | por |
| dc.identifier.uri | http://hdl.handle.net/10400.4/1721 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.subject | Inibidores da Angiogénese | por |
| dc.subject | Anticorpos Monoclonais | por |
| dc.subject | Neovascularização da Coróide | por |
| dc.subject | Miopia Degenerativa | por |
| dc.title | Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |